MedPath

Polyethylene glycol

Generic Name
Polyethylene glycol
Brand Names
Bi-peglyte, Clearlax, Colyte, Gavilax, Gavilyte-C, Gavilyte-G, Gavilyte-H and Bisacodyl, Gavilyte-N, Gentlelax, Gialax, Glycolax, Golytely, Healthylax, Miralax, Moviprep, Nulytely, Peglyte, Pegylax, Plenvu, Purelax, Suflave
Drug Type
Small Molecule
CAS Number
25322-68-3
Unique Ingredient Identifier
3WJQ0SDW1A
Background

Polyethylene glycol (PEG) is a synthetic polymer produced via polymerization of ethylene oxide molecules to make joining units of ethylene glycol by an ether linkage. PEGs are water-soluble polymers that can form hydrogen bonds in a ratio of 100 water molecules per one PEG molecule. Molecular weights of PEGs vary by time of the polymerization process and the molecular weight represents the weighted average of the individual PEG molecules. PEGs differ in their physical and chemical properties depending on their molecular weight: PEGs are liquids when molecular weights are <1000 and the molecule turns to waxy solids with increasing molecular weights. The most common preparations of PEGs include PEG 3350 and PEG 400. PEGs have various applications in many fields, ranging from medical to industrial areas. PEGs have a long history of gastroenterology: PEG 3350 is a common over-the-counter osmotic laxative used to relieve occasional constipation. PEG 3350 is also used for cleansing of the colon in preparation for colonoscopy in adults.

The rationale of using PEG in gastroenterology is due to the physical properties of the compound: its potent water-binding capacity, negligible intestinal absorption with increasing molecular mass, lack of significant toxicity, and limited intestinal enzymatic degradation or bacterial metabolism all make PEG a useful therapeutic agent for the treatment of occasional constipation and bowel cleansing for preparation in colonoscopy.

Indication

Polyethylene glycol is indicated for use as an over-the-counter osmotic laxative to relieve occasional constipation. When used in combination with sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride, it is used for cleansing of the colon in preparation for colonoscopy in adults.

Associated Conditions
Chronic Constipation, Constipation, Dry Eye Syndrome (DES), Dry Eyes, Occasional Constipation
Associated Therapies
Bowel preparation therapy, Eye lubrication

Effect of Adding Simethicone to Split-dose Polyethylene Glycol for Bowel Preparation in a Screening Colonoscopy Setting

Not Applicable
Completed
Conditions
Colonic Neoplasms
Colo-rectal Cancer
Interventions
First Posted Date
2019-01-25
Last Posted Date
2022-10-05
Lead Sponsor
Portuguese Oncology Institute, Coimbra
Target Recruit Count
412
Registration Number
NCT03816774
Locations
🇵🇹

Portuguese Oncology Institute - Coimbra, Coimbra, Portugal

Randomized Controlled Trail of Polyethylene Glycol vs Sodium Phosphate for Colonic Cleansing of Colonoscopy

Phase 4
Completed
Conditions
Polyethylene Glycol
Sodium Phosphate
Interventions
First Posted Date
2019-01-25
Last Posted Date
2020-04-17
Lead Sponsor
Dong Yang
Target Recruit Count
586
Registration Number
NCT03817788
Locations
🇨🇳

the First Hospital of Jilin University, Chang chun, Jilin, China

Reduction of Postoperative Gastrointestinal Dysmotility Following Total Laparoscopic Hysterectomy.

Phase 4
Completed
Conditions
Postoperative Passage of Flatus
Postoperative Bowel Movement
Interventions
First Posted Date
2019-01-11
Last Posted Date
2020-06-02
Lead Sponsor
The Cleveland Clinic
Target Recruit Count
81
Registration Number
NCT03800745
Locations
🇺🇸

Cleveland Clinic Florida, Weston, Florida, United States

Study Comparing the Bowel Cleansing Efficacy of PLENVU® Versus SELG-ESSE® Using a 2-Day Split Dosing Regimen.

Phase 4
Completed
Conditions
Colon Polyp
Colon Lesion
Colon Adenoma
Interventions
First Posted Date
2018-11-15
Last Posted Date
2020-08-27
Lead Sponsor
Istituto Clinico Humanitas
Target Recruit Count
399
Registration Number
NCT03742232
Locations
🇮🇹

ISMETT, Palermo, Italy

🇮🇹

Fondazione Poliambulanza, Brescia, Italia, Italy

🇮🇹

Humanitas Research Hospital, Rozzano, Italy

and more 2 locations

Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a

First Posted Date
2018-10-25
Last Posted Date
2023-04-14
Lead Sponsor
Eiger BioPharmaceuticals
Target Recruit Count
407
Registration Number
NCT03719313
Locations
🇺🇸

University of Miami Schiff Center for Liver Disease, Miami, Florida, United States

🇮🇹

Azienda Ospedaliero Universitaria di Parma, Parma, Italy

🇮🇹

Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Roma, Italy

and more 113 locations

A Predictive Model for Inadequate Bowel Preparation

Not Applicable
Completed
Conditions
Bowel Preparation
Interventions
First Posted Date
2018-10-15
Last Posted Date
2019-11-01
Lead Sponsor
Shandong University
Target Recruit Count
429
Registration Number
NCT03704571
Locations
🇨🇳

Qilu Hospital of Shandong University, Jinan, Shandong, China

Dried Plums (Prunes) vs. Polyethylene Glycol 4000 for Treatment of Functional Constipation in Children

Phase 3
Conditions
Functional Constipation
Interventions
Other: Prunus domestica
First Posted Date
2018-08-20
Last Posted Date
2018-08-23
Lead Sponsor
Medical University of Warsaw
Target Recruit Count
110
Registration Number
NCT03639142

Extended Administration of Polyethylene Glycol (PEG) Interferon Alfa-2b in Participants With Solid Tumors (C/I97-349/MK-4031-009)

Phase 1
Completed
Conditions
Neoplasms
Interventions
First Posted Date
2018-06-12
Last Posted Date
2019-07-15
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
29
Registration Number
NCT03554005

Safety and Tolerability of PRO-087 Versus Xyel Ofteno® and Systane Ultra®, on the Ocular Surface of Healthy Subjects

Phase 1
Completed
Conditions
Lubricant Allergy
Dry Eye Syndromes
Tear Disorder
Interventions
Drug: PRO-087
Drug: Xyel Ofteno
First Posted Date
2018-05-14
Last Posted Date
2019-07-19
Lead Sponsor
Laboratorios Sophia S.A de C.V.
Target Recruit Count
30
Registration Number
NCT03524157
Locations
🇲🇽

Private Ophthalmological Office, Zapopan, Jalisco, Mexico

Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin

Phase 1
Withdrawn
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
First Posted Date
2018-04-13
Last Posted Date
2020-02-25
Lead Sponsor
Queen Mary University of London
Registration Number
NCT03498222
© Copyright 2025. All Rights Reserved by MedPath